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Abstract
Background: The global pandemic of obesity has led to an increased risk for prediabetes and type-2 diabetes
(T2D). The aims of the current project are: (1) to evaluate the effect of a 22-week family based intervention
program, including supervised exercise, on insulin resistance syndrome (IRS) risk in children with a high risk of
developing T2D and (2) to identify the profile of microRNA in circulating exosomes and in peripheral blood
mononuclear cells in children with a high risk of developing T2D and its response to a multidisciplinary
intervention program including exercise.
Methods: A total of 84 children, aged 8–12 years, with a high risk of T2D will be included and randomly assigned
to control (N = 42) or intervention (N = 42) groups. The control group will receive a family based lifestyle education
and psycho-educational program (2 days/month), while the intervention group will attend the same lifestyle
education and psycho-educational program plus the exercise program (3 days/week, 90 min per session including
warm-up, moderate to vigorous aerobic activities, and strength exercises). The following measurements will be
evaluated at baseline prior to randomization and after the intervention: fasting insulin, glucose and hemoglobin
A1c; body composition (dual-energy X-ray absorptiometry); ectopic fat (magnetic resonance imaging); microRNA
expression in circulating exosomes and in peripheral blood mononuclear cells (MiSeq; Illumina); cardiorespiratory
fitness (cardiopulmonary exercise testing); dietary habits and physical activity (accelerometry).
Discussion: Prevention and identification of children with a high risk of developing T2D could help to improve
their cardiovascular health and to reduce the comorbidities associated with obesity.
Trial registration: ClinicalTrials.gov, ID: NCT03027726. Registered on 16 January 2017.
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Background
Type-2 diabetes (T2D) is an important cause of prema-
ture death and disability as well as a costly disease affect-
ing more than 415 million people worldwide [1]. This
chronic disease is an important risk factor for developing
accelerated cardiovascular disease and is the leading
cause of microvascular complications such as end-stage
renal disease, blindness and limb amputations. T2D was
traditionally viewed as an adult-onset disease; however,
over the last two decades scientific literature shows a
global and dramatic increase in the incidence of T2D in
youth [2], secondary to the coincident pandemic of
childhood obesity [3]. The life-time risk of developing
microvascular and macrovascular complications and
mortality in early adulthood can be expected to be
higher when the onset is already in children/adolescents
rather than in adults with T2D or insulin resistance syn-
drome (IRS) due to the longer duration of the disease
and greater duration of glycemic exposure [2, 4, 5].
As a consequence of the high rates of obesity and dia-
betes risk, health and scientific organizations demand
urgent early preventive actions for increasing life expect-
ancy and quality of life of overweight/obese children at a
high risk of T2D [1, 6, 7]. T2D in youth is largely pre-
ventable through lifestyle intervention programs based
on increasing physical activity levels, improving dietary
habits and promoting a healthy body weight [8]. Like-
wise, overweight and obesity are the strongest risk fac-
tors for insulin resistance and T2D [9, 10]. However,
long-term success rates of lifestyle intervention pro-
grams focused on T2D prevention or treatment in chil-
dren are usually less than 10% [11]. The etiology of this
apparent inefficiency of lifestyle intervention programs is
multifactorial: lack of multidisciplinary approaches, high
rates of depression or anxiety which affect the adherence
to the program, insufficient involvement of the parents,
etc. [12–14]. Therefore, there is a need for studies exam-
ining the effect of family based multidisciplinary inter-
vention programs on metabolic abnormalities closely
associated to T2D risk in order to give appropriate treat-
ment/prevention options for prediabetes and T2D in
overweight/obese children.
In adults, lifestyle intervention programs based on diet
and physical activity level modifications have proven to
be effective in decreasing the rate of the progression
from glucose intolerance or prediabetes to T2D [6].
However, body mass loss achieved reducing energy in-
take is the cornerstone to the treatment in adults [6]. In
children, energy restriction programs may compromise
healthy growth and development, and increase the risk
of disordered eating behaviors.
There is substantial evidence indicating that lifestyle be-
haviors associated to obesity and T2D are established in
childhood and are difficult to modify into adulthood [15].
The adoption of healthy dietary habits is essential in the
prevention of the onset of T2D in children at high risk of
T2D. Consumption of sugar-sweetened beverages [16],
energy-dense diets [17], reduced consumption of fiber,
fruits and vegetables [18, 19], breakfast and meal skipping
[20] or eating frequency [21] have been consistently asso-
ciated with obesity and T2D risk. In addition, previous
studies have shown the association of low physical activity
levels and sedentary behaviors with insulin resistance in
children [22]. Moreover, short sleep duration and poor
sleep quality have been proposed as predictors of obesity
and T2D onset in children and adults [23, 24].
Family based lifestyle modification interventions (i.e.,
targeting both the child and parent) seem to be the most
efficacious treatment format for childhood obesity [25].
In addition, psychological and emotional factors are im-
portant determinants of lifestyle modifications [26] and
depressive symptoms and psychological stress have
negative effects on dietary behaviors and physical activity
levels [27]. Moreover, overweight/obese children have an
impaired psychological wellbeing compared to their non-
overweight peers [28]. In this context, multicomponent
lifestyle management aiming to promote healthy dietary
and sleep habits, increase physical activity levels and re-
duce sedentary behaviors may contribute to the preven-
tion of T2D in the short and the long term [29, 30].
Exercise is a critical component for T2D prevention
and management. Likewise, regular physical activity im-
proves insulin sensitivity in diabetic or prediabetic chil-
dren [31]. Previous studies have shown that exercise
training reduces insulin resistance in overweight/obese
youth, even without body mass loss [32]. Interestingly,
Davis et al. reported that the benefit of aerobic training
on insulin resistance was dose-dependent in overweight
children regardless of sex and race [33]. However,
although exercise is recommended for overweight/obese
children, optimal exercise prescription describing type
(aerobic training, resistance training or combined train-
ing) and intensity (moderate or vigorous) of exercise
needed to reduce T2D risk in children is unclear.
Obesity, insulin resistance and T2D are caused by a
combination of genetic, epigenetic and environmental
factors such as diet and exercise. During the last few
years, a growing number of studies demonstrate that
small, non-coding, ribonucleic acid (RNA) molecules
that function as regulators of gene expression, microRNAs
(miRNAs), may be involved in the pathogenesis of obesity,
diabetes and related metabolic disorders [34, 35]. Several
studies observed that miRNAs play a significant role in in-
sulin production and secretion, pancreatic islet develop-
ment and β-cell differentiation, and that they are
implicated in several aspects of glucose homeostasis and
lipid metabolism associated with the pathogenesis and
progress of T2D and obesity [36–38]. The stability and
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presence of miRNAs in a variety of readily accessible cell
types including body fluids, as well as their often tissue-
and disease-specific expression, and the possibility to
measure them with high sensitivity and specificity, render
them a potential source of clinical biomarkers of T2D risk
[39]. Moreover, miRNAs reflect individual biological
adaptations to physiological changes or environmental ex-
posures such as diet or exercise. Likewise, measurement
of miRNAs presents an opportunity to evaluate biological
changes associated with lifestyle interventions for the
reduction of metabolic disorders associated with T2D risk
such as insulin resistance, ectopic fat accumulation,
inflammation, etc. The majority of the studies aiming to
identify miRNAs as biomarkers of obesity and T2D have
been conducted in small samples of adults. Previous re-
ports observed changes in circulating miRNA profile after
metformin therapy [38] or exercise in prediabetic adults
[40]. In obese children, several miRNAs have been pro-
posed as biomarkers of endothelial dysfunction and
dyslipidemia [41]. As far as we are aware, there are no pre-
vious studies identifying the profile of miRNAs in children
at a high risk of T2D and its response to a family based
multidisciplinary intervention program including exercise.
Therefore, the primary aims of the PREDIKID (Preven-
tion of Diabetes in Kids) study are: (1) to evaluate the effect
of a 22-week, family based, multidisciplinary intervention
program including exercise on IRS in children with a high
risk of developing T2D and (2) to identify the profile of
microRNA in circulating exosomes and in peripheral blood
mononuclear cells in children with a high risk of developing
T2D and its response to a family based multidisciplinary
intervention program including exercise.
Methods
Design
The PREvention of DIabetes in KIDs (PREDIKID) study
is a randomized clinical trial (RCT) (ClinicalTrials.gov,
ID: NCT03027726) (see Additional file 1 and Fig. 1 for
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials SPIRIT Figure. cIMT carotid intima media thickness; CRF
cardiorespiratory fitness; HDL high-density lipoprotein; SAAT subcutaneous abdominal fat; TG triglycerides; VAT visceral abdominal fat
Arenaza et al. Trials  (2017) 18:372 Page 3 of 12
the associated Standard Protocol Items: Recommenda-
tions for Interventional Trials (SPIRIT) Checklist and
Figure, respectively). Children will be randomly allocated
to the control group or the exercise group and will be
followed for 22 weeks. All the families included in the
study will participate in a lifestyle education and psycho-
educational program conducted by a multidisciplinary
team of health care professionals (physicians, nutrition-
ists and dieticians, psychologists and exercise specialist)
and scientists. As both groups will receive the same life-
style education and psycho-education program, differ-
ences in changes in outcome variables will be due to the
additional effect of the exercise intervention. This study
was reviewed and approved by the Ethics Committee of
Clinical Investigation of Euskadi. All parents or legal
guardians will sign an informed written consent and all
the children will give their assent before being enrolled
in the study. The informed consent will be obtained by
the pediatricians participating in the recruitment.
Participants and selection criteria
Participants will be recruited by pediatricians from the
Pediatric Endocrinology Unit of the University Hospital
of Txagorritxu and from primary care clinics (Vitoria-
Gasteiz, Spain). Children aged between 8 and 12 years,
meeting the international criteria for classification of
T2D risk [1, 42], and having at least one parent or care-
giver willing to participate in the program sessions, will
be included (Table 1).
A pre-screening appointment will be scheduled with
the investigation team to assess eligibility, family needs
and commitment. Parents will provide the child’s and
family health history and detailed contact information.
After completion of the informed consent process, chil-
dren will undergo anthropometric screening (height,
body mass and waist circumference), complete physical
examination and blood sampling, and will be selected
for inclusion in the study if they meet the inclusion cri-
teria (Table 1). Every child meeting the inclusion criteria
will go through maximal exercise testing guarantee.
Children with any medical condition that could affect
the results of the study or that limits physical activity
will be excluded.
Sample size calculation
Insulin resistance is the primary outcome of this study.
We expect that pre-post intervention differences in our
design consisting in two experimental groups, control
and exercise group, will have a size effect (Cohen’s d) of
0.7 for insulin resistance (i.e., homeostatic model assess-
ment, HOMA) (N = 34 in each group, 80% power and α
of 0.05). These effect size estimates are based on previ-
ous studies performed in overweight children with simi-
lar age range and a with intervention programs
including supervised exercise [33, 43, 44]. We observed
in one previous study, in which the effect of the same
intervention program was tested on hepatic fat in over-
weight/obese children, losses to follow-up of approxi-
mately 7% (data not shown). Previous studies have
reported losses to follow-up of between 4 and 17%. As-
suming a maximum loss of follow-up of 20%, we decided
to recruit a total of 84 children (50% girls), 42 children
for each group.
Randomization
Eligible participants will be randomly assigned after
completing the baseline measurements to either the con-
trol group or the or exercise group (Fig. 2).
Randomization of the participants into the control or
exercise group will be done using Statistical Package for
Social Sciences (IBM SPSS Statistics for Windows, ver-
sion 21, Armonk, NY, USA) by an independent re-
searcher. Assessment staff will be blinded to participant
randomization assignment. Participants and their par-
ents or guardians will be explicitly informed of the group
to which they will be assigned, as well as of the study hy-
potheses. As exercise is potentially beneficial for the
health of the children recruited in this trial, the waiting
list control group strategy will be used, which means
that the control group will receive the same exercise
program when the post-intervention evaluations are
finished.
Family based healthy lifestyle education and psycho-
educational intervention
Families in the control and the exercise groups will at-
tend both the healthy lifestyle education and psycho-
Table 1 Eligibility criteria for the PREvention of DIabetes in KIDs
(PREDIKID) study
Inclusion criteria
Aged 8–12 years
Criteria for the classification of risk of T2D [1]a
1. Obesity status according to the World Obesity Federation [24] 2.
Overweight and the presence of at least one of the following metabolic
abnormalities: 2.1. Family history of T2D in first- or second-degree relative;
Signs of insulin resistance or conditions associated with insulin resistance
(acanthosis nigricans, HOMA> 2.5, glucose between 100 and 125 mg/dL;
Hypertension (systolic blood pressure≥ 130 mmHg and/or diastolic
blood pressure≥ 85 mmHg); Dyslipidemia (HDL < 40 mg/dL, TG> 150
mg/dL); 2.2. Ethnic minority with higher risk
To have at least one parent or caregiver willing to participate in the
program sessions
Exclusion criteria
Not available for assessment and intervention sessions
Medical conditions or medications that would affect study results or
limit physical exercise
PREDIKID PREvention of DIabetes in Kids. aAccording to the International
Diabetes Federation [1]. T2D type-2 diabetes; TG triglycerides; HDL
high-density lipoprotein; HOMA homeostatic model assessment
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education program once every 2 weeks (11 sessions over
22 weeks) for 90 min (45 min in the healthy lifestyle edu-
cation program and 45 min in the psycho-educational
intervention). The design of the programs has been pub-
lished elsewhere [45]. Briefly, the sessions of the healthy
lifestyle education and psycho-educational interventions
will be developed simultaneously and delivered to both
parents (or caregivers) and children, separately.
The family based healthy lifestyle education program
will be conducted by experienced nutritionists. The aim
of the program will be in promoting changes in lifestyle
behaviors strongly associated to obesity and T2D risk:
promoting healthy dietary habits (reducing the intake of
sugar, sugar-sweetened beverages and energy-dense
foods, enhancing the daily consumption of fruits and
vegetables, promoting breakfast and eating five meals/
day), increasing regular physical activity levels, reducing
time spent in sedentary behaviors and promoting sleep
hygiene and adequate sleep duration.
The aims of the psycho-educational program will be to
provide parental skills to optimize the family environment
in order to make positive changes in their lifestyles and to
learn assertive communication skills. The program will
also provide skills to children for managing the emotions
and feelings that they are experiencing and to improve
their self-esteem and psychological wellbeing.
Exercise training intervention
The exercise group will do exercise 3 days/week, 90 min
per session, over a 22-week period. The program will be
open to the families 5 days per week to choose a total of
3 days/week. Sessions will be designed and supervised by
exercise specialists. The design of the exercise program
has been published elsewhere [45]. Briefly, the program
consists of cardiovascular endurance (60 min) and
muscle strength exercises (10 min). The sessions also
include 10 min of warm-up period, 5 min for giving
instructions and 5 min of cool-down period at the end,
consisting mainly of stretching exercises. Moderate to
vigorous intensity aerobic workout is the main part of
the exercise session (60 min) and consists of games,
circuits and start-and-stop activities. The emphasis of
the program is on intensity doing special emphasis on
high intensity activities (above 75% of maximal heart
rate (HRmax) obtained from either the cardiopulmonary
exercise test in the laboratory or the 20-m shuttle run
test) and enjoyment. Participants will wear a heart rate
monitor (Polar RS300X) during the exercise sessions to
Fig. 2 Planned study design
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ensure achievement of the target heart rate zone. Heart
rate monitors will be programmed according to individ-
ual percentage of HRmax as follows: (1) very light inten-
sity: from 50 to 57% of HRmax, (2) light intensity:
from >57 to 64% of HRmax, (3) moderate intensity,
from >64 to 76% HRmax, (4) high intensity or vigorous:
from >76 to 96% HRmax and (5) maximal intensity: >
96% of HRmax.
Participant retention and adherence
The success of the intervention is strongly dependent on
enjoyment and active participation. In order to motivate
children’s active participation, the staff will use several
strategies to celebrate success achieving the proposed
objectives in both the healthy lifestyle education and the
exercise programs: celebrate and recognize their efforts,
reward with smiley emoticons, etc. Children who
complete the program successfully will be rewarded with
a certificate of completion. The attendance to the life-
style education and psycho-education programs and of
the exercise program will be recorded. Children will be
marked as absent when: (1) the child does not attend
the exercise session or does not participate in the pro-
posed activities and (2) the child and at least one parent/
caregiver do not attend one session of the healthy life-
style education and psycho-educational programs.
Outcome measures for the first objective
IRS and the risk of T2D is characterized by excess adi-
posity, low levels of insulin sensitivity, dyslipidemia and
hypertension. In the current project, the primary out-
come is insulin resistance. Secondary outcome variables
include total, abdominal and visceral adiposity, ectopic
fat (hepatic and pancreatic fat), cardiorespiratory fitness,
cardiovascular disease risk factors and inflammation
markers, hepatokines and adipokines (Table 2). Primary
and secondary outcomes will be evaluated at baseline
and repeated after 22 weeks of intervention (Fig. 2).
Post-intervention measurements will be scheduled
within 3 days following the last healthy lifestyle program
session or exercise session in the control or in the exer-
cise group, respectively.
Primary outcome measure: insulin resistance
HOMA has been shown to be the more reliable method
to assess insulin resistance in children [46]. The
computer-generated HOMA will be used [47].
Secondary outcomes
Anthropometry and blood pressure Body mass (SECA
760), height (SECA 220) and waist circumference (SECA
200) will be measured following standard protocols at
least twice until consistent measures are obtained and,
thereafter, Body Mass Index (BMI) and waist to height
ratio will be calculated. Systolic and diastolic blood
pressure measurements will be performed following the
recommendations for children [48] using an arm blood
pressure oscillometric monitor device (OMRON® M6).
Total, abdominal and visceral adiposity In children,
the role of total, abdominal and visceral fat accumulation
in the development of IRS, and ultimately T2D, is well
established. One recent report observed that every add-
itional 1% of adiposity at 8–10 years decreased insulin
sensitivity by 2.9% 2 years later [22]. Total and abdom-
inal adiposity will be measured by dual energy X-ray ab-
sorptiometry (HOLOGIC, QDR 4500 W). Visceral
adiposity will be measured by magnetic resonance im-
aging using a 1.5-T system (MAGNETOM Avanto, Sie-
mens Healthcare, Erlangen, Germany) equipped with a
phased-array surface coil and a spine array coil. Auto-
mated visceral fat measurement will be achieved by
image processing (Matlab, Matworks Inc., Natick, MA,
USA).
Ectopic fat Excess adiposity is associated with an accu-
mulation of fat in multiple organs and tissues. Fat accu-
mulation in the liver and pancreas promotes a pro-
inflammatory state that may increase the risk of insulin
resistance and T2D. Likewise, ectopic fat accumulation
seems to be an important predictor of the onset of T2D
in adolescents [49]. Insulin sensitivity was 55% lower in
adolescents with hepatic steatosis compared to those
without fatty liver disease. Few studies have examined
fat accumulation in the pancreas and its relationship
with insulin resistance and T2D. Pancreatic steatosis seems
to be associated with prediabetes in children increasing the
risk of T2D and cardiovascular disease [50–52]. Neverthe-
less, other studies reported no significant associations of
pancreatic fat and β-cell dysfunction [53]. There are no
previous studies examining the effect of either a lifestyle
modification program or an exercise program on pan-
creatic fat. Hepatic and pancreatic fat will be mea-
sured by magnetic resonance imaging using a 1.5-T
system (MAGNETOM Avanto, Siemens Healthcare,
Erlangen, Germany) equipped with a phased-array
surface coil and a spine array coil.
Cardiorespiratory fitness Cardiorespiratory fitness is
an independent predictor of T2D in adults [54]. In
youths, there is evidence indicating a negative associ-
ation between cardiorespiratory fitness and insulin re-
sistance [55]. Moreover, previous reports suggested that
that the relationship between cardiorespiratory fitness
and T2D may be mediated by an increased susceptibility
to fat deposition in liver and pancreas, increasing
thereby insulin resistance [49, 56]. Cardiorespiratory fit-
ness will be assessed by two different tests as published
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elsewhere [45]: (1) the 20-m shuttle run test [57]. We
will use the equation reported by Léger et al. [57] to esti-
mate the maximum oxygen consumption (VO2max, ml/
kg/min) from the 20-m shuttle run test scores and (2)
direct cardiopulmonary exercise progressive incremental
treadmill test using the modified American College of
Sports Medicine protocol with respiratory gas analysis to
exhaustion [58].
Carotid intima-media thickness Early changes of ath-
erosclerosis can be detected assessing carotid intima-
media thickness (cIMT). In adolescents with T2D, Shah
et al. reported that every 1% increase in hemoglobin A1c
(HbA1c) or each year increase of the duration of the
disease was associated with 30% higher cIMT [59]. In
children with obesity, cIMT was higher in those with
prediabetes than in their counterparts with normal
glucose tolerance [60]. cIMT will be measured by ultra-
sound (General Electric, Logic S8 model) according to
international recommendations. All studies will be done
following a standardized scanning protocol for the right
and left common carotid arteries. The common carotid
artery bulb will be identified and the segments of com-
mon carotid arteries 1–2 cm proximal to the bulb region
will be scanned. During the end of the diastole cIMT
will be measured in both carotids four times and mean
cIMT and maximal cIMT will be calculated. Also in tele-
diastole, two sides of maximal diameter of the common
carotid, bulb and internal carotid will be measured.
Inflammation and biochemical cardiovascular disease
risk factors The obesity-associated chronic inflamma-
tory process participates in the onset of T2D, although
the underlying mechanisms are not well understood [61,
62]. Several studies have suggested that inflammatory
cytokines may influence insulin sensitivity, both directly
and also indirectly mediated, by adipokines, such as
leptin and adiponectin, and hepatokines such as fetuin-
A and fibroblast-21 growth factor (FGF-21) [62–65].
Biochemical variables will be measured from venous
Table 2 Summary of the methodology of primary and
secondary outcome measurements and potential confounders
in the PREvention of DIabetes in KIDs (PREDIKID) study
Measure Methodology
Primary outcomes
Insulin resistance Homeostatic model assessment
(HOMA), biochemical analyses
Expression of miRNA in circulating
exosomes and white blood cells
RNA-seq methodology
Secondary outcomes
Physical measures
Body mass (kg) Scale
Height (cm) Stadiometer
Waist circumference (cm) Non-elastic tape
Blood pressure (mmHg) Oscillometric monitor device
Body fat (%) Dual X-ray absorptiometry
Abdominal adiposity (g) Dual X-ray absorptiometry
Visceral abdominal adiposity (cm2) Magnetic resonance imaging
Hepatic fat (%) Magnetic resonance imaging
Pancreatic fat (%) Magnetic resonance imaging
Carotid intima medial thickness
(mm)
Doppler ultrasonography
Biochemical measures
Glucose (mg/dL) Enzymatic spectrophotometry
Insulin, leptin, adiponectine,
fetuin-A, FGF21
Enzyme-Linked Immunosorbent
Assay
Hemoglobin A1c Enzymatic tests
Total cholesterol, HDL- and LDL
-cholesterol (mg/dL)
Enzymatic spectrophotometry
Triglycerides (mg/dL) Enzymatic spectrophotometry
Alanine aminotransferase (U/L) Enzymatic tests
Aspartate aminotransferase (U/L) Enzymatic tests
Gamma glutamyl transferase (U/L) Enzymatic tests
C-reactive protein (g/dL) Enzyme immunoassay
TSH, T3, T4 Radioimmunoassay
Uric acid (mg/dL) Enzymatic spectrophotometry
Urea, bilirubin Enzymatic spectrophotometry
Cardiorespiratory fitness 20-m shuttle run test
Cardiopulmonary exercise test
Dietary assessment 24-h recalls and food frequency
questionnaires
Physical activity assessment Accelerometry and questionnaires
Sleeping habits Accelerometry and questionnaires
Sedentary behaviors Questionnaires
Potential confounders
Pubertal development
(Tanner stage)
Physical examination
Table 2 Summary of the methodology of primary and
secondary outcome measurements and potential confounders
in the PREvention of DIabetes in KIDs (PREDIKID) study
(Continued)
Sociodemographic variables
Socioeconomic status Questionnaires
Neonatal variables Health booklets and
questionnaires
Family medical history Questionnaires
Demographic characteristics Questionnaires
PREDIKID Prevention of Diabetes in Kids; FGF21 fibroblast growth factor 21;
HDL high-density lipoprotein; LDL low-density lipoprotein; miRNA micro RNA;
TSH thyroid stimulating hormone; T3 triiodothyronine; T4 free thyroxine
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fasting blood samples obtained from each child by expe-
rienced nurses. Blood samples will be immediately cen-
trifuged, aliquoted and stored at −80 °C or below. This
permits the measurement of a full set of cardiovascular
markers including lipid profile (total cholesterol, HDL-
and LDL-cholesterol and triglycerides), glucose, insulin,
HbA1c, cytokines (e.g., tumor necrosis factor alpha and
interleukin (IL)-6) adipokines (e.g., leptin and adiponec-
tin), hepatokines (fetuin-A and FGF-21), liver enzymes
(alanine aminotransferase, aspartate aminotransferase
and gamma-glutamyl transferase), C-reactive protein
and uric acid. ELISA kits, Western blots and High Per-
formance Liquid Chromatography-Mass Spectroscopy
will be used to perform these analyses.
Physical activity, sedentary behavior, dietary assess-
ment and sleep We will assess all these lifestyle behav-
iors both at the beginning and the end of the
intervention. Children will wear an accelerometer on the
non-dominant wrist (ActiSleep, Actigraph, Pensacola,
FL, USA) for seven consecutive days for 24 h to record
physical activity intensity levels and patterns, as well as
sleeping habits and participants will also complete a
diary log. Sedentary behaviors, such as watching TV,
playing computer games, playing video games or phone
games and surfing the Internet, will be self-reported by
the children using validated questionnaires [66]. Dietary
intake will be evaluated by two non-consecutive 24-h re-
calls within a period of 7 days by nutritionists and a self-
reported semi-quantitative food frequency questionnaire.
Outcome measures for the second objective
Recently, miRNAs have emerged as key regulators of
gene expression. T2D is associated with changes in the
level of several miRNAs in pancreatic β-cells as well as
in tissues such as liver, skeletal muscle or adipose tissue
[67, 68]. Moreover, miRNA expression seems to partici-
pate in the regulation of the IRS mediated by the regula-
tion of inflammatory processes [39]. As has been
mentioned in previous sections, the second primary aim
of the present work is to characterize the miRNA species
present in circulating white blood cells and exosomes,
before and after the intervention program is applied.
Our initial hypothesis is that the application of this pro-
gram will have a direct impact on the miRNA species
present in blood cells and exosomes, and that these
changes will influence the physiological effects elicited
by the exercise program.
Extraction and isolation of miRNAs from white blood cells
and plasma
Exosomes will be obtained from 1 ml of plasma using
the Total Exosome Isolation Kit (Thermo Fisher Scien-
tific) following manufacturer’s protocols. RNA molecules
will be isolated from white blood cells (buffy coat) and
exosomal fractions using Qiagen miRNeasy kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
instructions. Once isolated, RNA will be quantified using
a fluorimetric method.
Analysis and validation of miRNAs
Species of miRNA present on samples of individual sub-
jects, before and after the intervention program, will be
analyzed using RNA-seq methodology on Illumina’s
MiSeq Next Generation Sequencing system. This work-
flow allows one to fully characterize the miRNA profile
present in the samples analyzed (exosomes and white
blood cells) and to quantify the expression levels of dif-
ferent miRNA species. In this sense, effects of the inter-
vention program on the miRNA profile and on
expression level of specific species can be inferred.
Briefly, Illumina’s TruSeq Small RNA Sample prepar-
ation kit will be used to generate sequencing libraries,
from 1 μg of total RNA isolated from previous samples
(either exosomes or white blood cells). Only 145 to 160
bp libraries will be selected for sequencing, as they
include miRNA species (22–30 bp plus adapters).
Sequencing reactions will be performed on Illumina’s
MiSeq Reagent Kit V3, which supports to multiplex up
to 10 samples on a single run, and single reads of 50 nt
in length. Analysis of results, FASTQ files generation
and sequence alignment will be performed using specific
software packages (MiSeq Reporter, Bowtie, SAMtools,
DESeq2 and miRDeep).
Confounding variables
Puberty stage
At baseline, the pediatrician will evaluate Tanner staging
by direct-examination breast palpation in girls and
testicular measurement by orchidometer in boys.
Sociodemographic variables
Information about socioeconomic status, demographic
characteristics and family medical history of obesity, dia-
betes, dyslipidemia and hypertension will be collected.
Socioeconomic status will be evaluated using The Family
Affluence Scale [69] and parental education level and
parental occupation. As demographic characteristics,
date of birth, sex, ethnicity and family structure will be
recorded.
Assessment of side effects
All adverse effects or health problems attributable to the
testing or exercise sessions will be recorded.
Data management and monitoring
Participants’ data will be identified only by a study num-
ber (starting with 001) and only the principal
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investigator and study coordinator will have access to
identifiers that can link the data to the individual partici-
pant. Participants who drop out will be noted and their
reasons documented. Data will be entered and stored on
a standalone computer into excel and SPSS data files, and
the information will be password protected. We will
assure the quality of data entry by random checking of the
data entered. Study data is only accessible by the
researchers involved in the trial, and only the principal in-
vestigator and investigators in the project will have access
to the data for analysis. The investigators will monitor that
the informed consent process is conducted appropriately
and that informed consent was obtained prior to proceed-
ing with any study procedures. Only participants who
meet study eligibility criteria will be enrolled. Data will be
kept for 10 years after the research is completed and all
data (electronic and hard copy) will be destroyed after the
storage period. There is no data monitoring committee
due to the characteristics of the current study.
Data analyses plan
All outcome variables will be checked for normality and
results will be expressed as mean and standard deviation
(SD) or median and ranges. Multiple regression analyses
will be performed to examine the potential independent
predictors of T2D risk. At baseline, differences in
continuous variables between groups (control group vs.
exercise group) will be analyzed by Student’s t test or the
Mann-Whitney U test, as appropriate. Differences in
categorical variables at baseline between the two groups
will be explored by chi-squared tests. Repeated-
measured analysis of variance will be used to assess the
effect of exercise (time (pre-post 22-weeks’ interven-
tion) × group interactions) on the primary (insulin resist-
ance) and secondary study (adiposity, ectopic fat,
cardiorespiratory fitness, cardiovascular disease risk
factors, inflammation markers, etc.) outcomes and the
intention-to-treat principle will be applied. For sensitiv-
ity analyses, we will analyze the effect of the adherence
to the program on the results of the intervention.
Data dissemination plan
The principal investigator will inform the parents about
their child’s health before and after the intervention pro-
gram. The main results of the trial will be communi-
cated to the health care professionals (pediatricians) in
Vitoria-Gasteiz and other relevant groups (e.g., univer-
sity academics), as well as to the public. Scientific arti-
cles will be also written.
Discussion
The worldwide obesity pandemic and the increasing
prevalence of T2D at younger ages are important public
health issues with both individual and social costs.
Likewise, research focusing on the prevention of T2D in
pre-adolescent children is a high priority for public
health. Scientific associations emphasize the need for
evidence-based adiposity and IRS control treatments
that may reduce T2D risk in children at a high risk [6].
The primary aim of the PREDIKID project is to test
the effect of a multidisciplinary program including
supervised exercise in the reduction of IRS in pre-
adolescents at a high risk to develop T2D that could
serve as preventive model of T2D in childhood. The
families participating in the study will receive an educa-
tional program including lifestyle, psychological and
emotional aspects that the scientific literature implicates
in the development and progression of obesity and T2D
risk in childhood. Moreover, the exercise intervention of
the PREDIKID study will obtain objective data about the
effect of high intensity exercise on metabolic variables
closely associated to T2D risk in children, such as insu-
lin resistance, HbA1c, ectopic fat, total, abdominal and
visceral adiposity, cIMT, cardiorespiratory fitness, adipo-
kines, hepatokines and cytokines, blood pressure or lipid
profile. We will examine clinical outcomes intimately as-
sociated with T2D using innovative technology and ref-
erence methods. Likewise, the PREDIKID project will
help to better understand the relationship between hep-
atic and pancreatic fat and IRS and risk of T2D in chil-
dren. In addition, the current study may offer relevant
clinical information about the efficacy of a family based
multidisciplinary intervention program that includes ex-
ercise on reducing ectopic fat, IRS and cardiovascular
disease risk factors in children at a high risk of T2D.
The pathophysiology of childhood obesity and associ-
ated comorbidities, such as T2D, is not well established.
To date it is not clear why some children develop IRS and
T2D, while others show the metabolically healthy pheno-
type [70]. Biomarkers for early detection of children at risk
of T2D would greatly improve the care of children with
overweight/obesity. Hence, there is a need to search for
clinically relevant markers with prognostic value for inter-
vention success. Recently, miRNAs have been proposed as
promising biomarkers in terms of both diagnosis and
prognosis of obesity-related comorbidities [71, 72]. The
PREDIKID project will help to identify miRNAs poten-
tially associated with early onset of IRS in children with
overweight/obesity. Moreover, the differential expression
and responses in circulating miRNAs between the control
group and the exercise group may help to understand the
underlying mechanisms of the effect of exercise on IRS, as
well as to predict individual variability to the intervention
in overweight/obese children.
Trial status
The recruitment started on March 2017, and is expected
to finish in September 2018.
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